Datasheet | February 22, 2021

Increase The Probability Of Regulatory And Technical Success

Source: Medidata AI

Today’s clinical trials are becoming increasingly complex — with rising costs, a faster evolving treatment landscape and a growing risk of trial failure. To mitigate this uncertain landscape and make better data-driven decisions, clinical development groups have turned towards real world data (RWD) to augment and inform their understanding of the disease and treatment landscape.

The clinical development process for medical therapies has multiple aims, including

  • To produce the strongest possible scientific case for the efficacy & safety of the new treatment relative to a placebo or the standard-of-care to support approval by regulatory agencies
  • To make the strongest case to physicians, patients and payors for the value of the new treatment relative to the current standard of care

However, the challenge of finding and matching the right data to a development program means many decisions must be made without the strong supporting evidence that a clinical developer would desire.

Integrated Evidence from Acorn AI provides access to a one of a kind cross-sponsor, regulatory grade, patient-level clinical trial dataset with pre-integrated real world assets to help clinical developers make critical data-driven decisions throughout the product development lifecycle and increase their probability of success.

VIEW THE DATASHEET!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader